Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies
- PMID: 37562045
- DOI: 10.1002/eji.202250326
Toll-like receptors and IL-7 as potential biomarkers for immune-mediated necrotizing myopathies
Abstract
We aimed to verify whether the immune system may represent a source of potential biomarkers for the stratification of immune-mediated necrotizing myopathies (IMNMs) subtypes. A group of 22 patients diagnosed with IMNM [7 with autoantibodies against signal recognition particle (SRP) and 15 against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR)] and 12 controls were included. A significant preponderance of M1 macrophages was observed in both SRP+ and HMGCR+ muscle samples (p < 0.0001 in SRP+ and p = 0.0316 for HMGCR+ ), with higher values for SRP+ (p = 0.01). Despite the significant increase observed in the expression of TLR4 and all endosomal Toll-like receptors (TLRs) at protein level in IMNM muscle tissue, only TLR7 has been shown considerably upregulated compared to controls at transcript level (p = 0.0026), whereas TLR9 was even decreased (p = 0.0223). Within IMNM subgroups, TLR4 (p = 0.0116) mRNA was significantly increased in SRP+ compared to HMGCR+ patients. Within IMNM group, only IL-7 was differentially expressed between SRP+ and HMGCR+ patients, with higher values in SRP+ patients (p = 0.0468). Overall, innate immunity represents a key player in pathological mechanisms of IMNM. TLR4 and the inflammatory cytokine IL-7 represent potential immune biomarkers able to differentiate between SRP+ and HMGCR+ patients.
Keywords: Cytokines; Immune-mediated necrotizing myopathies (IMNMs); Innate immunity; Macrophages; Toll-like receptors.
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
References
-
- Allenbach, Y., Mammen, A. L., Benveniste, O. and Stenzel, W., the Immune-Mediated Necrotizing Myopathies Working Group, 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul. Disord. 2018. 28: 87-99.
-
- Day, J. A. and Limaye, V., Immune-mediated necrotising myopathy: a critical review of current concepts. Semin. Arthritis Rheum. 2019. 49: 420-429.
-
- Pinal-Fernandez, I., Casal-Dominguez, M., Carrino, J. A., Lahouti, A. H., Basharat, P., Albayda, J., Paik, J. J. et al., Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 2016. 76: 681-687.
-
- Watanabe, Y., Uruha, A., Suzuki, S., Nakahara, J., Hamanaka, K., Takayama, K., Suzuki, N. et al., Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J. Neurol. Neurosurg. Psychiatry 2016. 87: 1038-1044.
-
- Allenbach, Y. and Benveniste, O., Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Curr. Opin. Rheumatol. 2018. 30: 655-663.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
